{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:30:20Z","timestamp":1768890620377,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T00:00:00Z","timestamp":1489708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s11886-017-0844-z","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T08:15:22Z","timestamp":1489738522000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cardio-oncology: the Nuclear Option"],"prefix":"10.1007","volume":"19","author":[{"given":"Jorge A.","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond R.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"issue":"4","key":"844_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3322\/caac.21235","volume":"64","author":"CE DeSantis","year":"2014","unstructured":"DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252\u201371. doi: 10.3322\/caac.21235 .","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"844_CR2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","volume":"342","author":"GM Felker","year":"2000","unstructured":"Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077\u201384. doi: 10.1056\/NEJM200004133421502 .","journal-title":"N Engl J Med"},{"issue":"4","key":"844_CR3","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s12350-016-0538-8","volume":"23","author":"RR Russell","year":"2016","unstructured":"\u2022\u2022 Russell RR, Alexander J, Jain D, Poornima IG, Srivastava AV, Storozynsky E, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of cancer and cancer therapy. J Nucl Cardiol. 2016;23(4):856\u201384. doi: 10.1007\/s12350-016-0538-8 . This informational statement provides a useful summary of many of the currently used chemotherapeutic agents and their associated cardiovascular toxicities. In addition, it provides a comparison of all of the recommended monitoring protocols for anthracyclines and trastuzumab.","journal-title":"J Nucl Cardiol"},{"issue":"25","key":"844_CR4","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1200\/JCO.2007.10.9777","volume":"25","author":"JR Carver","year":"2007","unstructured":"Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007;25(25):3991\u20134008. doi: 10.1200\/JCO.2007.10.9777 .","journal-title":"J Clin Oncol"},{"issue":"5","key":"844_CR5","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215\u201321.","journal-title":"J Clin Oncol"},{"issue":"6","key":"844_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM197902083000603","volume":"300","author":"J Alexander","year":"1979","unstructured":"Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, Reduto L, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300(6):278\u201383. doi: 10.1056\/NEJM197902083000603 .","journal-title":"N Engl J Med"},{"issue":"6","key":"844_CR7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0002-9343(87)90212-9","volume":"82","author":"RG Schwartz","year":"1987","unstructured":"\u2022\u2022 Schwartz RG, McKenzie WB, Alexander J, Sager P, D\u2019Souza A, Manatunga A, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy : Seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82(6):1109\u201318. The first published recommendations for monitoring LVEF in patients receiving anthracyclines. Demonstrated a significant decrease in the development of clinical heart failure in patients whose management was congruent with the recommendations.","journal-title":"Am J Med"},{"issue":"2","key":"844_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1067\/mnc.2003.7","volume":"10","author":"I Mitani","year":"2003","unstructured":"Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003;10(2):132\u20139. doi: 10.1067\/mnc.2003.7 .","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"844_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jacc.2012.10.006","volume":"61","author":"V Mor-Avi","year":"2013","unstructured":"Mor-Avi V, Lang RM. Is echocardiography reliable for monitoring the adverse cardiac effects of chemotherapy? J Am Coll Cardiol. 2013;61(1):85\u20137. doi: 10.1016\/j.jacc.2012.10.006 .","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"844_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","volume":"61","author":"P Thavendiranathan","year":"2013","unstructured":"\u2022\u2022 Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol. 2013;61(1):77\u201384. doi: 10.1016\/j.jacc.2012.09.035 . This study demonstrated the importance of utilizing noncontrast 3D transthoracic echocardiography to other echocardiographic modalities in assessing patients for cardiotoxicity because of the low variability of the method.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"844_CR11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911\u201339. doi: 10.1016\/j.echo.2014.07.012 .","journal-title":"J Am Soc Echocardiogr"},{"issue":"7","key":"844_CR12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2006.07.003","volume":"48","author":"RC Hendel","year":"2006","unstructured":"Hendel RC, Patel MR, Kramer CM, Poon M, Hendel RC, Carr JC, et al. ACCF\/ACR\/SCCT\/SCMR\/ASNC\/NASCI\/SCAI\/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol. 2006;48(7):1475\u201397. doi: 10.1016\/j.jacc.2006.07.003 .","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 7","key":"844_CR13","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"\u2022\u2022 Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23 Suppl 7:vii155\u201366. doi: 10.1093\/annonc\/mds293 . The ESMO guidelines provide up-to-date protocols for monitoring cardiotoxicity for anthracyclines and trastuzumab that include the use of biomarkers in monitoring.","journal-title":"Ann Oncol"},{"issue":"5","key":"844_CR14","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jcmg.2010.03.003","volume":"3","author":"TC Gerber","year":"2010","unstructured":"Gerber TC, Gibbons RJ. Weighing the risks and benefits of cardiac imaging with ionizing radiation. JACC Cardiovasc Imaging. 2010;3(5):528\u201335. doi: 10.1016\/j.jcmg.2010.03.003 .","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"844_CR15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","volume":"15","author":"JR Mackey","year":"2008","unstructured":"Mackey JR, Clemons M, Cote MA, Delgado D, Dent S, Paterson A, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol. 2008;15(1):24\u201335.","journal-title":"Curr Oncol"},{"issue":"2","key":"844_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/MNM.0b013e328025ae04","volume":"28","author":"GS Panjrath","year":"2007","unstructured":"Panjrath GS, Jain D. Trastuzumab-induced cardiac dysfunction. Nucl Med Commun. 2007;28(2):69\u201373. doi: 10.1097\/MNM.0b013e328025ae04 .","journal-title":"Nucl Med Commun"},{"issue":"5","key":"844_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/annonc\/mdf132","volume":"13","author":"BV Jensen","year":"2002","unstructured":"Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13(5):699\u2013709. doi: 10.1093\/annonc\/mdf132 .","journal-title":"Ann Oncol"},{"issue":"11","key":"844_CR18","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","volume":"48","author":"N Kalay","year":"2006","unstructured":"Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48(11):2258\u201362. doi: 10.1016\/j.jacc.2006.07.052 .","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"844_CR19","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"\u2022\u2022 Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol. 2013;61(23):2355\u201362. doi: 10.1016\/j.jacc.2013.02.072 . This study demonstrated the cardioprotective effects of the combination of ACE inhibitor and beta-blocker in patients receiving anthracyclines.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"844_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213\u201320. doi: 10.1016\/j.jacc.2009.03.095 .","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"844_CR21","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/annonc\/mdu055","volume":"25","author":"C Lestuzzi","year":"2014","unstructured":"Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, et al. Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. Ann Oncol. 2014;25(5):1059\u201364. doi: 10.1093\/annonc\/mdu055 .","journal-title":"Ann Oncol"},{"issue":"4","key":"844_CR22","first-page":"167","volume":"3","author":"MH Abou El Fadl","year":"2009","unstructured":"Abou El Fadl MH, Bagai RK, Spiro TP, Daw HA. 5-Fluorouracil-induced cardiotoxicity during chemotherapy for adenocarcinoma of the small bowel. Gastrointest Cancer Res. 2009;3(4):167\u201370.","journal-title":"Gastrointest Cancer Res"},{"key":"844_CR23","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Hodgkins Lymphoma Version 3. 2016."},{"issue":"2","key":"844_CR24","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1542\/peds.2007-0575","volume":"121","author":"SM Shankar","year":"2008","unstructured":"Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children\u2019s Oncology Group. Pediatrics. 2008;121(2):e387\u201396. doi: 10.1542\/peds.2007-0575 .","journal-title":"Pediatrics"},{"issue":"2","key":"844_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd3252","volume":"10","author":"T Force","year":"2011","unstructured":"Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat Rev Drug Discov. 2011;10(2):111\u201326. doi: 10.1038\/nrd3252 .","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"844_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","volume":"5","author":"H Sawaya","year":"2012","unstructured":"\u2022\u2022 Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596\u2013603. doi: 10.1161\/CIRCIMAGING.112.973321 . This study demonstrated the utility of assessing global longitudinal strain in monitoring for cardiotoxicity.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"11","key":"844_CR27","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639\u201342. doi: 10.1038\/nm.2919 .","journal-title":"Nat Med"},{"issue":"5","key":"844_CR28","first-page":"842","volume":"45","author":"RJ Bennink","year":"2004","unstructured":"Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden JL, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med. 2004;45(5):842\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"844_CR29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","volume":"37","author":"P Spallarossa","year":"2004","unstructured":"Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, Nasti S, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol. 2004;37(4):837\u201346.","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"844_CR30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2310\/7290.2008.00015","volume":"7","author":"KL Gabrielson","year":"2008","unstructured":"Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Pin S, Tsao A, et al. Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99m annexin V single-photon emission computed tomography. Mol Imaging. 2008;7(3):132\u20138.","journal-title":"Mol Imaging"},{"issue":"12","key":"844_CR31","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/nm1201-1347","volume":"7","author":"J Narula","year":"2001","unstructured":"Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7(12):1347\u201352.","journal-title":"Nat Med"},{"issue":"2","key":"844_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.114.001952","volume":"8","author":"H Su","year":"2015","unstructured":"Su H, Gorodny N, Gomez LF, Gangadharmath U, Mu F, Chen G, et al. Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity. Circ Cardiovasc Imaging. 2015;8(2), e001952. doi: 10.1161\/CIRCIMAGING.114.001952 .","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"844_CR33","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mpo.1155","volume":"37","author":"H Hayakawa","year":"2001","unstructured":"Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37(1):4\u20139. doi: 10.1002\/mpo.1155 .","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"844_CR34","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mdf170","volume":"13","author":"D Cardinale","year":"2002","unstructured":"Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13(5):710\u20135.","journal-title":"Ann Oncol"},{"issue":"10","key":"844_CR35","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF00175059","volume":"18","author":"I Carrio","year":"1991","unstructured":"Carrio I, Estorch M, Berna L, Germa JR, Alonso C, Ojeda B, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med. 1991;18(10):806\u201312.","journal-title":"Eur J Nucl Med"},{"issue":"3","key":"844_CR36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/meta.2002.30506","volume":"51","author":"H Hirose","year":"2002","unstructured":"Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 2002;51(3):314\u20137.","journal-title":"Metabolism"},{"issue":"12","key":"844_CR37","first-page":"1965","volume":"31","author":"M Estorch","year":"1990","unstructured":"Estorch M, Carrio I, Berna L, Martinez-Duncker C, Alonso C, Germa JR, et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med. 1990;31(12):1965\u20139.","journal-title":"J Nucl Med"},{"issue":"11","key":"844_CR38","first-page":"2044","volume":"36","author":"I Carrio","year":"1995","unstructured":"Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med. 1995;36(11):2044\u20139.","journal-title":"J Nucl Med"},{"issue":"7","key":"844_CR39","first-page":"1062","volume":"42","author":"I Carrio","year":"2001","unstructured":"Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42(7):1062\u201376.","journal-title":"J Nucl Med"},{"issue":"20","key":"844_CR40","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.jacc.2010.01.014","volume":"55","author":"AF Jacobson","year":"2010","unstructured":"Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55(20):2212\u201321. doi: 10.1016\/j.jacc.2010.01.014 .","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"844_CR41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00003072-199203000-00001","volume":"17","author":"RA Valdes Olmos","year":"1992","unstructured":"Valdes Olmos RA, ten Bokkel Huinink WW, Greve JC, Hoefnagel CA. I-123 MIBG and serial radionuclide angiocardiography in doxorubicin-related cardiotoxicity. Clin Nucl Med. 1992;17(3):163\u20137.","journal-title":"Clin Nucl Med"},{"issue":"11","key":"844_CR42","first-page":"2060","volume":"36","author":"H Takano","year":"1995","unstructured":"Takano H, Ozawa H, Kobayashi I, Hamaoka S, Nakajima A, Nakamura T, et al. Atrophic nerve fibers in regions of reduced MIBG uptake in doxorubicin cardiomyopathy. J Nucl Med. 1995;36(11):2060\u20131.","journal-title":"J Nucl Med"},{"issue":"8","key":"844_CR43","first-page":"1283","volume":"34","author":"S Wakasugi","year":"1993","unstructured":"Wakasugi S, Fischman AJ, Babich JW, Aretz HT, Callahan RJ, Nakaki M, et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med. 1993;34(8):1283\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"844_CR44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/0959-8049(94)00357-B","volume":"31A","author":"RA Valdes Olmos","year":"1995","unstructured":"Valdes Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF, van Tinteren H, Bruning PF, van Vlies B, et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer. 1995;31A(1):26\u201331.","journal-title":"Eur J Cancer"},{"issue":"1","key":"844_CR45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2281.2001.00292.x","volume":"21","author":"T Nousiainen","year":"2001","unstructured":"Nousiainen T, Vanninen E, Jantunen E, Remes J, Kuikka J, Hartikainen J. Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clin Physiol. 2001;21(1):123\u20138.","journal-title":"Clin Physiol"},{"issue":"6","key":"844_CR46","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/BF03006439","volume":"17","author":"K Saito","year":"2003","unstructured":"Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med. 2003;17(6):481\u20138.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"844_CR47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.111.000364","volume":"1","author":"SM Banypersad","year":"2012","unstructured":"Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1(2), e000364. doi: 10.1161\/JAHA.111.000364 .","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"844_CR48","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/circulationaha.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312. doi: 10.1161\/circulationaha.116.021612 .","journal-title":"Circulation"},{"issue":"9","key":"844_CR49","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s00259-014-2832-5","volume":"41","author":"G Merlini","year":"2014","unstructured":"Merlini G, Narula J, Arbustini E. Molecular imaging of misfolded protein pathology for early clues to involvement of the heart. Eur J Nucl Med Mol Imaging. 2014;41(9):1649\u201351. doi: 10.1007\/s00259-014-2832-5 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"844_CR50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2967\/jnumed.111.102053","volume":"54","author":"G Antoni","year":"2013","unstructured":"Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjo L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213\u201320. doi: 10.2967\/jnumed.111.102053 .","journal-title":"J Nucl Med"},{"issue":"9","key":"844_CR51","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","volume":"41","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Semer J, Strader C, Bruyere Jr JR, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652\u201362. doi: 10.1007\/s00259-014-2787-6 .","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0844-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-017-0844-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-017-0844-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T21:45:11Z","timestamp":1568929511000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-017-0844-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s11886-017-0844-z","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]},"article-number":"31"}}